Informed Consent Disclosure to Vaccine Trial Subjects of Risk of COVID‐19 Vaccines Worsening Clinical Disease

“The specific and significant COVID‐19 risk of antibody-dependent enhancement (ADE) should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.”

Government officials knew about the risks of ADE before the authorizing the COVID “vaccines” for emergency use. (thanks for TLAV for getting this out)

Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease (nih.gov)

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

%d bloggers like this: